A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
Latest Information Update: 29 Dec 2023
At a glance
- Drugs Sofosbuvir (Primary) ; Ledipasvir/sofosbuvir; Sofosbuvir/velpatasvir; Sofosbuvir/velpatasvir/voxilaprevir; Voxilaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 14 Nov 2023 Results (n=132) assessing risk factors of HCC and characterize the natural history of HCC development in patients who have achieved SVR with sofosbuvir-based direct-acting antiviral therapy (DAA presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 04 Feb 2022 This trial has been completed in Germany (Date of the global end of the trial : 31-Dec-2021), according to European Clinical Trials Database record.
- 18 Jan 2022 Status changed from active, no longer recruiting to completed.